These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31204415)

  • 1. Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease.
    Sun S; Karsdal MA; Mortensen JH; Luo Y; Kjeldsen J; Krag A; Jensen MD; Bay-Jensen AC; Manon-Jensen T
    J Gastrointestin Liver Dis; 2019 Jun; 28():175-182. PubMed ID: 31204415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations.
    Minordi LM; Larosa L; Papa A; Bordonaro V; Lopetuso L; Holleran G; Gasbarrini A; Manfredi R
    J Gastrointestin Liver Dis; 2019 Jun; 28():213-224. PubMed ID: 31204402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
    Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A
    Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating D dimer in inflammatory bowel disease.
    Biancone L; Scopinaro F; Maletta M; Monteleone G; Luzza F; Banci M; Mercantini P; Renda T; Pallone F
    Ital J Gastroenterol; 1994 Apr; 26(3):116-20. PubMed ID: 8061337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application.
    Viennet C; Laurensou C; Goydadin AC; Faivre B; Muret P; Humbert P
    J Wound Care; 2014 Feb; 23(2):66-7, 70, 72. PubMed ID: 24526082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
    Mombelli G; Monotti R; Haeberli A; Straub PW
    Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
    de Bruyn M; Arijs I; De Hertogh G; Ferrante M; Van Assche G; Rutgeerts P; Vermeire S; Opdenakker G
    J Crohns Colitis; 2015 Dec; 9(12):1079-87. PubMed ID: 26351381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin.
    Lassila R; Peltonen S; Lepäntalo M; Saarinen O; Kauhanen P; Manninen V
    Arterioscler Thromb; 1993 Dec; 13(12):1738-42. PubMed ID: 8241093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin.
    Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
    J Lab Clin Med; 1995 Mar; 125(3):384-91. PubMed ID: 7897305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
    Gadducci A; Baicchi U; Marrai R; Del Bravo B; Fosella PV; Facchini V
    Gynecol Oncol; 1994 Jun; 53(3):352-6. PubMed ID: 8206409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test.
    Bach-Gansmo ET; Godal HC; Skjønsberg OH
    Thromb Res; 1998 Nov; 92(3):125-34. PubMed ID: 9806364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
    Weitz JI; Leslie B; Hudoba M
    Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease.
    Eritsland J; Seljeflot I; Arnesen H; Smith P; Westvik AB
    Thromb Res; 1992 Apr; 66(1):55-60. PubMed ID: 1412183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
    Widström O; Kockum C; Nilsson BS
    Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
    Lip GY; Lowe GD; Rumley A; Dunn FG
    Br Heart J; 1995 Jun; 73(6):527-33. PubMed ID: 7626351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmatic parameters of fibrin formation and degradation in cancer patients: correlation between fibrinopeptide A and D-dimer.
    Sagripanti A; Carpi A; Baicchi U; Grassi B
    Biomed Pharmacother; 1993; 47(6-7):235-9. PubMed ID: 8061250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
    Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
    Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Early Atherosclerosis Markers in Patients with Inflammatory Bowel Disease.
    Üstün Y; Kilincalp S; Çoban Ş; Coşkun Y; Yüksel İ; Ongun A; Soykan İ; Bektaş M; Törüner M; Çetinkaya H; Örmeci N
    Med Sci Monit; 2016 Oct; 22():3943-3950. PubMed ID: 27773920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.